ABOUT US
Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary IdyllaTM Platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology. Today, Biocartis offers tests supporting melanoma, colorectal, lung, breast, thyroid, brain, blood and liver cancer.
Biocartis is headquartered in Mechelen, Belgium.
Mission & Vision
Measuring the presence of a biomarker associated with a patient’s tumor can provide crucial information whether a patient is eligible for a new generation of more effective targeted treatments, i.e., personalized medicine. This provides great opportunities for better health outcomes and reduced healthcare costs for patients, healthcare providers, payors and society.
In molecular diagnostics, current technologies are often complex. They require a lot of hands-on time and are difficult to implement in the local laboratory. Sending out samples to specialized centers delays results, preventing rapid initiation of the most beneficial therapy. However, rapid access to accurate data about the relevant cancer mutations or treatment resistance in oncology is vital. Early disease interception means less anxiety while waiting for results and faster initiation of the best possible treatment.
Biocartis’ vision is to enable personalized medicine for patients around the world through universal access to molecular testing. Our mission is to make molecular testing actionable, easy, fast and suitable for any lab.
MEET IDYLLA™
The Idylla™ Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction)-based system designed to offer easy, in-house molecular biomarker testing in only 3 hours, allowing fast and optimal treatment selection and disease progress monitoring.
